Current trends for biosimilars in the Latin American market

Category: Review Article
Author(s): , , , , , , , ,
Visits: 185 total, 1 today
Keywords: biologicals, biopharmaceuticals, biosimilars, Latin America

The number of approved biological medicines in the global pharmaceutical market has been increasing over recent decades. However, their high costs have motivated the manufacture of biosimilar products, following expiry of the patent on the reference drug. Biosimilar drugs are approved medicines of biological origin, which have no statistically significant differences in terms of quality, safety and therapeutic efficacy to the reference product. Across the world, regulation has been developed to ensure the safety and efficacy of biosimilar products. By virtue of the fact that biosimilars can reduce public health expenditure and increase patient access to biological medicines, Latin America has recently begun to invest in the development of these drugs. The objective of this literature review is to describe how the biosimilar market is developing in Latin America.

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply